+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Muscle Spasm Market: By Causes, By Drugs & By Region - Forecast 2016-2021

  • ID: 3973844
  • Report
  • 162 pages
  • IndustryARC
1 of 3
Muscle spasm is involuntary, sudden contraction of muscle or group of muscles of the body. Muscle spasm is also known as muscle cramp or involuntary hypertonicity. Globally, development of efficient and advance technology, Rise in the demand for athlete activities and support the growth of muscle spasm market are the prime growth drivers of global Muscle Spasm market. In addition, increase in adoption of of Muscle Spasm for newer applications, and emerging economies such as China, India and others, will create new opportunities for global Muscle spasm market. However, higher cost of the research and development, Limited diagnosis and self-limiting nature of the disease are the key restraints for global Nanotechnology Drug Delivery market.

Muscle Spasm Market

Geographically North America dominated global Muscle Spasm market, and Europe is projected to have fastest growth, owing to rapidly increasing awareness of muscle spasm, its causes and effects and its treatments. Asia-Pacific is considered as an untapped market due to lack of proper healthcare facilities in some Asian countries, and modernizing infrastructure in developing nations such as China, and India in this region. Among all the causes, Muscular injury has the highest market share in global Muscle Spasm market.

This report identifies the global Muscle Spasm market size in for the year 2014-2016, and forecast of the same for year 2021. It also highlights the potential growth opportunities in the coming years, while also reviewing the market drivers, restraints, growth indicators, challenges, market dynamics, competitive landscape, and other key aspects with respect to global Muscle Spasm market.

This report segments global Muscle Spasm market on the basis of cause, drugs, end-user, and regional market as follows:

Muscle Spasm Market, By Causes : muscular injury, spinal nerve compression, sprains and strains of the muscle diabetic ketoacidosis, others and Others
Muscle Spasm Market, By Drugs: Diazepam, quinine, phonation, carbamazepine and others
The report has focused study on Muscle Spasm market by basis of end-user such as: Construction, Fire-Fighting, Sports Apparel, Automotive, Aerospace, Military & Defence, Industrial, and Others
This report has been further segmented into major regions, which include detailed analysis of each region such as: North America, Europe, Asia-Pacific (APAC), and Rest of the World (RoW) covering all the major country level markets in each of the region. The major countries considered under the Asia-Pacific region are India, China, South Korea and Japan. The major countries considered under the European region are Germany, U.K., France, Italy, Spain and Russia. The major countries considered under the North American region are United States, Canada and Mexico

This report identifies all the major companies operating in the Muscle Spasm market. Some of the major companies’ profiles in detail are as follows:

Amgen, Inc
Eisai Co., Ltd
Novartis International AG
GlaxoSmithKline plc
AstraZeneca plc
Please Note: The report is to be delivered in 1-2 working days after an order is placed.
Note: Product cover images may vary from those shown
2 of 3
1. Muscle Spasm Market – Market Overview

2. Executive Summary

3. Market Landscape
3.1. Market Share Analysis
3.2. Comparative Analysis
3.3. Product Benchmarking
3.4. End User Profiling
3.5. Top 5 Financials Analysis

4. Muscle Spasm Market– Market Forces
4.1. Drivers
4.1.1. Development of efficient and advance technology
4.1.2. Rise in the demand for athlete activities
4.1.3. support the growth of muscle spasm market
4.2. Restraints
4.2.1. Limited diagnosis
4.2.2. self-limiting nature of the disease
4.2.3. high cost of R&D
4.3. Opportunities
4.3.1. Emerging economies
4.3.2. Increase in adoption of Muscle Spasm treatment
4.4. Challenges
4.5. Porter’s Five Forces Analysis
4.5.1. Bargaining Power of Suppliers
4.5.2. Bargaining Power of Buyers
4.5.3. Threat of New Entrants
4.5.4. Threat of Substitutes
4.5.5. Degree of Competition

5. Muscle Spasm Market– Strategic Analysis
5.1. Value Chain Analysis
5.2. Pricing Analysis
5.3. Opportunities Analysis
5.4. Product/Market Life Cycle Analysis
5.5. Suppliers and Distributors

6. Muscle Spasm Market, By Causes
6.1. Muscular injury
6.2. Spinal nerve compression
6.3. Sprains and strains of the muscle diabetic ketoacidosis
6.4. others

7. Muscle Spasm Market, By Drug
7.1. Diazepam
7.2. Quinine
7.3. Phonation
7.4. Carbamazepine
7.5. Others

8. Muscle Spasm Market, By Geography
8.1. Europe
8.1.1. Germany
8.1.2. France
8.1.3. Italy
8.1.4. Spain
8.1.5. Russia
8.1.6. U.K.
8.1.7. Rest of Europe
8.2. Asia Pacific
8.2.1. China
8.2.2. India
8.2.3. Japan
8.2.4. South Korea
8.2.5. Rest of Asia-Pacific
8.3. North America
8.3.1. U.S.
8.3.2. Canada
8.3.3. Mexico
8.4. Rest of the World (RoW)
8.4.1. Brazil
8.4.2. Rest of RoW

9. Muscle Spasm – Market Entropy
9.1. Expansion
9.2. Technological Developments
9.3. Merger & Acquisitions, and Joint Ventures
9.4. Supply- Contract

10. Company Profiles (Overview, Financials, SWOT Analysis, Developments, Product Portfolio)
10.1. Amgen, Inc
10.2. Eisai Co., Ltd
10.3. Novartis International AG
10.4. GlaxoSmithKline plc
10.5. AstraZeneca plc
10.6. Pfizer, Inc
10.7. F. Hoffmann La Roche Ltd
10.8. Uniprot
10.9. Biotool
10.10. Bayer AG
*More than 40 Companies are profiled in this Research Report, Complete List available on Request*
"*Financials would be provided on a best efforts basis for private companies"

11. Appendix
11.1. Abbreviations
11.2. Sources
11.3. Research Methodology
11.4. Bibliography
11.5. Compilation of Expert Insights
11.6. Disclaimer
Note: Product cover images may vary from those shown
3 of 3


4 of 3